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Whether patients with severe aortic stenosis (AS) die because of AS-related causes is an important issue 
for the management of these patients. We used data from CURRENT AS registry, a Japanese multicenter 
registry, to assess the causes of death in severe AS patients and to identify the factors associated with 
non-cardiac mortality. We enrolled 3815 consecutive patients with a median follow-up of 1176 days; the 
1449 overall deaths comprised 802 (55.3%) from cardiac and 647 (44.7%) from non-cardiac causes. Heart 
failure (HF) (25.7%) and sudden death (13.0%) caused the most cardiac deaths, whereas infection (13.0%) 
and malignancy (11.1%) were the main non-cardiac causes. According to treatment strategies, infection 
was the most common cause of non-cardiac death, followed by malignancy, in both the initial aortic valve 
replacement (AVR) cohort (N = 1197), and the conservative management cohort (N = 2618). Both non-
cardiac factors (age, male, body mass index <22, diabetes, prior history of stroke, dialysis, anemia, and 
malignancy) and cardiac factors (atrial fibrillation, ejection fraction <68%, and the initial AVR strategy) 
were associated with non-cardiac death. These findings highlight the importance of close monitoring of non-
cardiac comorbidities, as well as HF and sudden death, to improve the mortality rate of severe AS patients.
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Aortic stenosis (AS) is the most common valvular disease worldwide. AS predominantly affects the elderly 
because age-related degenerative changes are the main etiologies. Older patients with AS have more comorbid-
ities1. In patients with AS who undergo surgical or transcatheter interventions, detailed causes of deaths have 
previously been reported2–6. In a systematic review, non-cardiac deaths accounted for approximately half of the 
mortalities beyond 30 days after transcatheter aortic valve implantation (TAVI)6. In the PARTNER trial cohort 
B, the non-cardiovascular mortality rate was 43% at 2 years5. Causes of death are often analyzed in selected 
cohorts, such as candidates for surgical aortic valve replacement, or in randomized controlled studies wherein 
the relatively strict enrollment criteria limit participation. Although the natural course of AS is well known, there 
is limited literature on the exact causes of death in the population of patients with severe AS that was managed 
conservatively in the contemporary era2,7. High risk surgical candidates no longer undergo classical surgery, but 
receive TAVI, as do inoperable patients8. Theoretically, these patients are more likely to die because of non-cardiac 
causes.
Recently, we reported a multicenter observational registry characterized by the enrollment of all consecutive 
patients who met the criteria of severe AS in real clinical practice9,10. The present study aimed to investigate 
the cardiac and non-cardiac causes of death in patients with severe AS and to assess the associated factors with 
non-cardiac deaths in this cohort. The investigation of the causes of death can provide knowledge crucial to 
answer the question if the patients with AS die from AS-related causes or not, and how we should manage the 
patients in the era in which TAVI is becoming widely used.
Methods
The CURRENT AS (Contemporary outcomes after sURgery and medical tREatmeNT in patients with severe 
Aortic Stenosis) registry enrolled 3815 consecutive patients with severe AS from 27 centers (on-site surgical facil-
ities in 20 centers) in Japan between January 2003 and December 2011 (Appendix material)9. We searched the 
hospital database for transthoracic echocardiography and enrolled consecutive patients who met the definition of 
severe AS on their index echocardiography (peak aortic jet velocity [Vmax] >4.0 m/s, mean aortic pressure gra-
dient [PG] >40 mm Hg, or aortic valve area [AVA] <1.0 cm2) for the first time during the study period. The study 
design and patient enrollment in the registry were previously described in detail9. Briefly, among the 3815 study 
patients, 1197 patients were managed with the initial aortic valve replacement (AVR) strategy, while 2618 patients 
were managed with the conservative strategy. In the present analysis, we (1) evaluated the cumulative incidence 
of all-cause, cardiac, and non-cardiac death during follow-up in the entire study population, (2) analyzed detailed 
causes of mortality according to the initial treatment strategies, and (3) determined the factors associated with 
non-cardiac mortality.
The study protocol was approved by the institutional review board of each participating center and was car-
ried out in accordance with the approved guidelines. Given the retrospective nature of the study, the require-
ment of written informed consent was waived. All patients agreed to participate in the study when contacted for 
follow-up. The patient records/information was anonymized prior to analysis.
The CURRENT AS clinical events committee reviewed the documentation concerning every death that 
occurred after enrollment. The cause of death was classified according to the VARC (Valve Academic Research 
Consortium) definitions and adjudicated by a clinical event committee11. Sudden death was defined as unex-
plained death in a previously stable patient. Every death was placed into one of the 2 categories in the CURRENT 
AS registry: (1) cardiovascular deaths, which consist of heart failure (HF), aortic valve procedure death, myo-
cardial infarction, sudden death, infective endocarditis, stroke, renal failure, aortic/peripheral vascular disease, 
other cardiac cause, and unknown death; and (2) non-cardiovascular deaths, which include malignancy, infec-
tion, respiratory failure, liver failure, renal failure, bleeding, trauma, and others9. In the present study, in order 
to distinguish cardiac causes from extra-cardiac causes, we used cardiac death and non-cardiac death instead of 
cardiovascular death and non-cardiovascular death, with deaths due to stroke and peripheral artery disease cat-
egorized as non-cardiac death because the thromboembolic events could result from the atherosclerotic burden. 
The classification of the causes of death is presented in Supplementary Table 1. Anemia was defined according to 
the World Health Organization criteria (hemoglobin <12.0 g/dL in women and <13.0 g/dL in men). The results 
of the two-dimensional transthoracic echocardiography were analyzed at baseline. The left ventricular ejection 
fraction (LVEF) was measured using the Teichholz method or the modified Simpson’s rule method.
Statistical analysis. Categorical variables were expressed as numbers and percentages. Continuous varia-
bles were expressed as means (SD) or medians with interquartile range (IQR).
The cumulative incidences of all-cause, cardiac, and non-cardiac death were assessed by the Kaplan-Meier 
method. Causes of deaths in the conservative management and initial AVR cohorts were presented according to 
the intention-to-treat principle regardless of whether AVR was actually performed. We developed a cause-specific 
Cox proportional hazard model for non-cardiac death, and assessed the factors associated with non-cardiac 
death. Consistent with our previous study9, we included 22 clinically relevant variables listed in Supplementary 
Table 2 and the treatment strategy at baseline in the model for non-cardiac death, and calculated the adjusted 
hazard ratios (HRs) and 95% confidence intervals (CIs).
All statistical analyses were conducted by two physicians (E.M. and T.K.) and a statistician (T.M.) using JMP 
10.0.2 (SAS Institute Inc., Cary, North Carolina). All P values were 2-tailed, and the level of statistical significance 
was set at P < 0.05.
Results
Baseline characteristics. The mean age of the current study population was 77.8 ± 9.8 years, and 1443 
(38%) patients were male. At baseline, there were 2005 symptomatic patients (53%), and 1808 asymptomatic 
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 14723  | DOI:10.1038/s41598-017-15316-6
patients (47%), excluding 2 patients without information on symptoms. Of the study population, 70% had hyper-
tension, 24% had diabetes mellitus, 15% had end-stage renal disease, and 55% had anemia. A history of malig-
nancy was documented in 14% of patients, and 3.9% of patients were currently under treatment for malignancy. 
The median Society of Thoracic Surgeons (STS) score was 3.8 (IQR: 2.2–16.7). The mean LVEF was 63 ± 14% and 
the mean Vmax was 4.1 ± 0.9 m/s (Supplementary Table 2).
Incidence and causes of death during follow-up. The median follow-up period was 1176 (IQR: 733–
1618) days, with a 93% follow-up rate at 2 years. Of the 1449 observed deaths, 802 deaths (55.3%) were cardiac 
and 647 deaths (44.7%) were non-cardiac (Fig. 1). The Kaplan-Meier curves showed a constant increase in cardiac 
death as well as non-cardiac death, with cumulative 5-year incidences of 43.1%, 26.6%, and 22.5% for all-cause, 
cardiac, and non-cardiac death, respectively (Fig. 2). HF and sudden death were the two leading causes of cardiac 
death, followed by procedure (AVR/TAVI)-related death (Fig. 3). Infection and malignancy were the two leading 
causes of non-cardiac death, followed by cerebrovascular death and renal failure (Fig. 3).
Causes of death according to management strategy. Regarding the initial treatment strategies, 2618 
patients were managed conservatively, while 1197 patients were managed with the initial AVR strategy. In the 
conservative management cohort, there were 674 cardiac deaths and 539 non-cardiac deaths. In the initial AVR 
cohort, there were 128 cardiac deaths and 108 non-cardiac deaths. Procedure-related death was the leading cause 
of cardiac death in the initial AVR cohort, followed by HF and sudden death. In the conservative management 
cohort, HF was the leading cause of cardiac death, followed by sudden death. Infection was the most common 
cause of non-cardiac death, followed by malignancy, in both cohorts (Supplementary Figure 1).
The factors independently associated with non-cardiac deaths. The factors independently asso-
ciated with non-cardiac deaths are provided in Table 1. Age, male sex, body mass index <22, diabetes in insulin 
therapy, prior symptomatic stroke, prior history of atrial fibrillation, dialysis, anemia, malignancy currently under 
treatment, LVEF below 68%, and the initial AVR strategy were associated with non-cardiac mortality (Table 1).
Discussion
The main findings of this study are as follows: (1) HF and sudden death are the top two causes of cardiac death 
whereas infection and malignancy are the top two causes of non-cardiac death in patients with severe AS; and (2) 
according to the results of the cause-specific analysis, LVEF <68%, atrial fibrillation, and the initial AVR strategy 
along with age, male sex, body mass index <22, and comorbidities, are the factors associated with non-cardiac 
death.
The impact of non-cardiac death was not negligible in patients with severe AS, although cardiac death was 
the main contributor to the overall mortality. In patients who were treated surgically, the most common cause of 
cardiac death was procedure-related death, reflecting the perioperative risk in the current patients with severe 
AS, followed by HF as the second most frequent cause of death. As anticipated, patients with severe AS who were 
managed conservatively were more likely to die of cardiac causes, such as HF and sudden death. A certain pro-
portion of this conservatively-managed cohort is thought to be candidates of TAVI, but also those with disabilities 
prohibitive for surgery or TAVI, and those who refused surgery9,12. The main non-cardiac causes of death in the 
entire population and in each strategy were infection and malignancy. These findings highlight the importance 
of paying close attention to the non-cardiac comorbidities. In patients who were managed surgically, the risk of 
cardiac death was substantially decreased after surgery1,4,6, increasing the impact of non-cardiac death afterwards. 
Given that TAVI, which is widely employed in intermediate- to high-risk patients with severe AS13, decreases 
mortality and positively affects symptoms and functional status, non-cardiac death can contribute much more to 
the overall mortality in patients who undergo TAVI.
Figure 1. Study patient flow. AVR = aortic valve replacement, AS = aortic stenosis.
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We used cause-specific Cox hazard models to determine the factors associated with non-cardiac death, because we 
focused on the etiologies of non-cardiac deaths14,15. This study revealed that the multiple factors related to non-cardiac 
deaths can be divided into the two large categories: non-cardiac factors (comorbidities, age, male sex, anemia, etc.) 
and cardiac factors. Non-cardiac factors were tightly linked to non-cardiac deaths. Prior stroke, diabetes on insulin 
therapy, and dialysis might indicate the increased atherosclerotic burden16–18; anemia suggested possible iron defi-
ciency, chronic inflammation, and malignancy19. Furthermore, low LVEF was related to non-cardiac death. Poor LV 
function is suggested to cause cardiac cachexia20 and may affect systemic immunity21,22, which leads to non-cardiac 
deaths such as infection and malignancy. Atrial fibrillation is associated with an increased incidence of cerebrovas-
cular death23. The initial AVR strategy was associated with a lower risk of non-cardiac death, for which there might 
be three possible reasons. First, there is the possibility that AVR improved the systemic condition through improve-
ment of the cardiac status. Second, patients managed with the initial AVR strategy might have been more closely 
followed-up at the outpatient department. Third, patients managed with the initial AVR strategy did not include those 
with disabilities prohibitive for surgery and those who refused surgery because of their limited life expectancy, which 
might not be adequately adjusted by the measured confounders. Although a cause–effect relationship between these 
above factors and non-cardiac deaths could not be demonstrated in the present study, cardiac factors may be linked to 
non-cardiac deaths and would be the possible therapeutic targets in patients with severe AS.
Figure 2. Cumulative incidence of all-cause, cardiac, and non-cardiac death.
Figure 3. Causes of death. CD = cardiac death, and NCD = non-cardiac death.
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Limitations. This study has several limitations. First, we did not show a statistical difference in the causes of 
death, because comprehensive presentation of mortality data was the main purpose of this study. Categorization 
of the circumstances surrounding each death, particularly the mechanism of death, were related to the process of 
adjudication and may be incomplete. Second, the present results in Japan cannot be easily generalized to reflect 
those of other countries and the world population. Third, this is a retrospective, observational, and epidemiolog-
ical investigation mainly from the pre-TAVI era. Finally, there remains unmeasured confounders affecting the 
mortality in the multivariable models exploring the risk factors associated with non-cardiac death.
Conclusions
Among cardiac deaths in severe AS patients (55.3%), HF and sudden death were the two main causes in the 
entire and conservative management cohorts. Procedure-related death was the leading cause of cardiac death in 
the initial AVR cohort. In addition, death from non-cardiac causes (44.7%), including death from infection and 
malignancy, is an important contributor to mortality in patients with severe AS.
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